Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVAXNovavax$9.46-0.9%$8.14$5.01▼$14.70$1.54B2.744.46 million shs5.00 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVAXNovavax0.00%+10.64%+19.75%+43.12%-30.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVAXNovavax$9.46-0.9%$8.14$5.01▼$14.70$1.54B2.744.46 million shs5.00 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVAXNovavax0.00%+10.64%+19.75%+43.12%-30.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVAXNovavax 2.00Hold$14.2951.01% UpsideCurrent Analyst Ratings BreakdownLatest NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025NVAXNovavaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)8/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.007/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVAXNovavax$1.08B1.42N/AN/A($3.89) per share-2.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVAXNovavax-$187.50M$2.284.15118.250.1239.20%-142.33%28.65%11/11/2025 (Estimated)Latest NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipNVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableNVAX HeadlinesRecent News About These CompaniesNovavax (NVAX) Is Up 10.6% After Sanofi Expands Matrix-M Licensing Agreement - Has the Bull Case Changed?October 4 at 2:14 PM | finance.yahoo.comA Fresh Look at Novavax (NVAX) Valuation After Recent Share Price ReboundOctober 3 at 4:09 PM | finance.yahoo.comInvestors Purchase Large Volume of Call Options on Novavax (NASDAQ:NVAX)October 2, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Trading 6.4% Higher - What's Next?October 1, 2025 | marketbeat.comNovavax (NVAX) Exceeds Market Returns: Some Facts to ConsiderSeptember 30, 2025 | zacks.comNovavax Amends Deal With Sanofi, Broadens PartnershipSeptember 30, 2025 | msn.comNovavax Announces Progress on Sanofi AgreementSeptember 30, 2025 | prnewswire.comBrokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $14.29September 28, 2025 | americanbankingnews.comHere's Why Novavax (NVAX) is a Strong Momentum StockSeptember 26, 2025 | zacks.comNovavax Inc. stock underperforms Thursday when compared to competitorsSeptember 25, 2025 | marketwatch.comHere is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending StockSeptember 25, 2025 | zacks.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by BrokeragesSeptember 25, 2025 | marketbeat.comNovavax (NVAX) Declines More Than Market: Some Information for InvestorsSeptember 23, 2025 | zacks.comKingstone Capital Partners Texas LLC Takes $1.02 Million Position in Novavax, Inc. $NVAXSeptember 22, 2025 | marketbeat.comChallenging Market Dynamics and Regulatory Hurdles Lead to Sell Rating for NovavaxSeptember 21, 2025 | tipranks.comNovavax: Endlessly Frustrating, Endlessly Fascinating - Warrants Rating UpgradeSeptember 18, 2025 | seekingalpha.comThe Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its DebutSeptember 18, 2025 | investors.comHere's Why Novavax (NVAX) Fell More Than Broader MarketSeptember 17, 2025 | zacks.comU.S. health insurers pledge continuing coverage of COVID shots ahead of ACIP meetingSeptember 17, 2025 | msn.comNovavax (NASDAQ:NVAX) Trading Up 5.1% - Time to Buy?September 17, 2025 | marketbeat.comGoldman Sachs Group Inc. Has $5.25 Million Stake in Novavax, Inc. $NVAXSeptember 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVAX Company DescriptionsNovavax NASDAQ:NVAX$9.46 -0.09 (-0.94%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$9.45 -0.01 (-0.14%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
